MCID: CRV038
MIFTS: 59

Cervical Squamous Cell Carcinoma malady

Categories: Reproductive diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Cervical Squamous Cell Carcinoma

About this section
Sources:
11Disease Ontology, 13DISEASES, 31ICD10 via Orphanet, 35LifeMap Discovery®, 45NCIt, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS
See all MalaCards sources

Aliases & Descriptions for Cervical Squamous Cell Carcinoma:

Name: Cervical Squamous Cell Carcinoma 35 11 54 50 13 68
Squamous Cell Carcinoma of the Cervix Uteri 11 54
 
Squamous Cell Carcinoma of Cervix 11

Classifications:



External Ids:

Disease Ontology11 DOID:3744
NCIt45 C4028
SNOMED-CT62 254886006
Orphanet54 ORPHA213767
ICD10 via Orphanet31 C53.0, C53.1, C53.8

Summaries for Cervical Squamous Cell Carcinoma

About this section
Disease Ontology:11 A cervix carcinoma that has material basis in squamous cells of the cervix.

MalaCards based summary: Cervical Squamous Cell Carcinoma, also known as squamous cell carcinoma of the cervix uteri, is related to microinvasive cervical squamous cell carcinoma and cervical intraepithelial neoplasia. An important gene associated with Cervical Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways are TP53 network and RHO GTPases activate IQGAPs. Affiliated tissues include cervix, uterus and lung, and related mouse phenotypes are Decreased viability and pigmentation.

Related Diseases for Cervical Squamous Cell Carcinoma

About this section

Diseases related to Cervical Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 143)
idRelated DiseaseScoreTop Affiliating Genes
1microinvasive cervical squamous cell carcinoma12.2
2cervical intraepithelial neoplasia11.4
3cervicitis10.9
4salivary gland adenoid cystic carcinoma10.7CDKN2A, TP53
5biliary papillomatosis10.7CDKN2A, TP53
6adenoid squamous cell carcinoma10.6CDKN2A, TP53
7amelogenesis imperfecta local hypoplastic10.6CDKN2A, MKI67, TP63
8simple partial epilepsy10.6CDKN2A, TP53
9split hand split foot malformation autosomal recessive10.6CDKN2A, MKI67, TP53
10intraductal papilloma10.6EGFR, OSMR
11tamoxifen-related endometrial lesion10.6EGFR, TP53
12oral tuberculosis10.6CDH1, TP53
13oral pharyngeal disorders10.6CDKN2A, MKI67, TP53
14ampulla of vater squamous cell carcinoma10.5CDKN2A, TP53
15peptic ulcer disease10.5EGFR, MKI67, TP53
16herpes simplex10.5CDKN2A, EGFR, TP53
17early myoclonic encephalopathy10.5CDKN2A, EGFR, TP53
18adenosquamous pancreas carcinoma10.5CDKN2A, EGFR
19stampe sorensen syndrome10.5EGFR, MKI67, TP53
20hypoglossal nerve neoplasm10.5CDKN2A, SOX2, TP53
21renal pelvis inverted papilloma10.5CDH1, TP53
22grade iii astrocytoma10.5CDKN2A, EGFR, TP53
23mantle cell lymphoma10.5CDKN2A, EGFR, TP53
24vitreoretinochoroidopathy dominant10.5EGFR, HLA-DRB1
25angiokeratoma circumscriptum10.5CDKN2A, EGFR, TP53
26animal phobia10.5EGFR, TP53
27ascending colon cancer10.5CDKN2A, SOX2, TP53
28duodenal somatostatinoma10.5CDKN2A, EGFR, TP53
29cervical benign neoplasm10.4EGFR, HLA-DRB1, TP53
30yolk sac tumor of central nervous system10.4EGFR, TP53
31cystoisosporiasis10.4CDKN2A, SERPINB3, TP53
32urticaria10.4CDKN2A, EGFR, TP53
33camera marugo cohen syndrome10.4KRT8, TP53
34autoimmune hemolytic anemia10.4CDKN2A, EGFR, SERPINB3
35sulfhemoglobinemia10.4CDKN2A, SERPINB3, TP53
36nasopharyngeal carcinoma10.4CDKN2A, EGFR, TP53
37cerebellum cancer10.4EGFR, TP53
38sialolithiasis10.4CDKN2A, MKI67, TP53, TP63
39bladder verrucous squamous cell carcinoma10.4CDKN2A, TP53, TYMP
40verloove vanhorick brubakk syndrome10.4EGFR, RASSF1, TP53
41vulva fibroepithelial polyp10.4CDKN2A, TP53
42colver steer godman syndrome10.4CDH1, TP53
43epithelioid trophoblastic tumor10.4CDKN2A, TP53, TYMP
44dental caries10.4CDH1, EGFR, TP53
45tumor predisposition syndrome10.4CDH1, CDKN2A, TP53
46ovarian wilms' cancer10.4CDH1, EGFR, TP53
47oral lichen planus10.4CDH1, EGFR, TP53
48novak syndrome10.4EGFR, MKI67, TP53, TP63
49x-linked congenital generalized hypertrichosis10.4CDKN2A, HLA-DRB1, MKI67, TP53
50giant cell glioblastoma10.4CDKN2A, EGFR, TP53

Graphical network of the top 20 diseases related to Cervical Squamous Cell Carcinoma:



Diseases related to cervical squamous cell carcinoma

Symptoms & Phenotypes for Cervical Squamous Cell Carcinoma

About this section

GenomeRNAi Phenotypes related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00381-A-19.6CDH1, CDKN2A, DAPK1, EGFR, SOX2

MGI Mouse Phenotypes related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

41 (show all 14)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.2CDKN2A, CTNNB1, EGFR, SOX2, TP53
2MP:00053708.4CDKN2A, CTNNB1, EGFR, KRT8, OSMR, RASSF1
3MP:00053818.4CDH1, CDKN2A, CTNNB1, EGFR, KRT8, SOX2
4MP:00053808.4CDH1, CDKN2A, CTNNB1, EGFR, KRT8, SOX2
5MP:00020068.4CDH1, CDKN2A, CTNNB1, EGFR, RASSF1, SOX2
6MP:00107718.3CDH1, CDKN2A, CTNNB1, EGFR, OSMR, SOX2
7MP:00030128.3CDH1, CDKN2A, CTNNB1, EGFR, OSMR, SOX2
8MP:00028738.3CDH1, CTNNB1, EGFR, MKI67, RASSF1, SOX2
9MP:00053897.7CDH1, CDKN2A, CTNNB1, EGFR, KRT8, SKP2
10MP:00053797.6CDH1, CDKN2A, CTNNB1, EGFR, OSMR, RASSF1
11MP:00053847.4CDH1, CDKN2A, CTNNB1, DAPK1, EGFR, RASSF1
12MP:00053887.3CDKN2A, CTNNB1, EGFR, SERPINB4, SOX2, TP53
13MP:00053766.8CDH1, CDKN2A, CTNNB1, DAPK1, EGFR, KRT8
14MP:00053876.3CDH1, CDKN2A, CTNNB1, EGFR, KRT8, OSMR

Drugs & Therapeutics for Cervical Squamous Cell Carcinoma

About this section

Drugs for Cervical Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 500)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
FluorouracilapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1179151-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
2
EthanolapprovedPhase 4, Phase 1204364-17-5702
Synonyms:
(C6-C9)Alkyl alcohol
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
1-Hydroxyethane
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
AC1L19TW
AC1Q31MM
AHD 2000
AI3-01706
ALCOHOL 5% IN D5-W
Absolute Alcohol
Absolute Ethanol
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethanol [German]
Aethylalkohol
Alcare Hand Degermer
Alcohol
Alcohol (USP)
Alcohol (ethyl)
Alcohol Anhydrous
Alcohol [USP]
Alcohol anhydrous
Alcohol dehydrated
Alcohol denatured
Alcohol etílico
Alcohol, Absolute
Alcohol, Dehydrated
Alcohol, Diluted
Alcohol, Grain
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, ethyl
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool Ethylique
Alcool Etilico
Alcool ethylique
Alcool etilico
Alcool éthylique
Algrain
Alkohol
Alkohol [German]
Alkoholu Etylowego
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C00469
C2H5OH
C2H6O
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
CHEMBL545
CID702
Caswell No. 426
Caswell No. 430
Colamine
Cologne Spirit
Cologne spirit
Cologne spirits
 
D000431
D00068
DB00898
Dehydrated Ethanol
Dehydrated alcohol
Dehydrated ethanol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured Ethanol
Denatured alcohol
Denatured ethanol
Desinfektol EL
Diluted Alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
EOH
EOX
ETA
Envision Conditioner Pdd 9020
Esumiru WK 88
EtOH
Etanolo
Etanolo [Italian]
Ethanol (9CI)
Ethanol 200 Proof
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol Vapor
Ethanol [JAN]
Ethanol solution
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl Alcohol Anhydrous
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl Hydrate
Ethyl Hydroxide
Ethyl alc
Ethyl alcohol
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl hydrate
Ethyl hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
Grain alcohol
HSDB 531
HSDB 82
HYDROXYETHYL GROUP
Hinetoless
Hydroxyethane
I14-12648
IMS 99
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated Spirit Mineralised
Methylated spirit
Methylcarbinol
MolPort-001-785-844
Molasses alcohol
NCGC00091458-01
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
SY Fresh M
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spiritus vini
Spirt
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
UNII-3K9958V90M
USAF EK-1597
Undenatured Ethanol
WLN: Q2
absolute alcohol
alcohol
alcohol etilico
bmse000297
etanol
ethanol
ethyl alcohol
grain alcohol
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
spiritus vini
Äthanol
Äthylalkohol
éthanol
3
Gefitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1351184475-35-2123631
Synonyms:
184475-35-2
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
Gelfitinib
HMS2089B19
I01-1227
 
IRE
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZD1839
ZINC19632614
gefitinib
nchembio.117-comp18
nchembio866-comp14
4
CetuximabapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1737205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
 
Cetuximabum
Cétuximab
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
cetuximab
5
CisplatinapprovedPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1269015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
6
Fentanylapproved, illicit, investigational, vet_approvedPhase 4, Phase 3773437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
1-phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl CII
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
 
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
UNII-UF599785JZ
fentanyl
7
CevimelineapprovedPhase 4, Phase 35107233-08-983898, 25137844
Synonyms:
(+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate
(+/-)cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate
(2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride
107233-08-9
153504-70-2
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
AC1L36EF
AC1L36GD
AC1NR4MS
AC1OCEXD
AF 102B
AF-102B
AF102B
BIDD:GT0265
C10H17NOS
CHEMBL1200362
CID5284532
CID6918023
CID83898
CID83927
Cevimelina
Cevimeline
Cevimeline (INN)
Cevimeline HCl 1/2H2O
Cevimeline [INN]
 
Cevimeline hydrochloride
Cevimeline hydrochloride (USAN)
Cevimeline hydrochloride [USAN]
Cevimeline hydrochloride hemihydrate
Cevimeline hydrochloride hydrate
Cevimeline hydrochloride hydrate (JAN)
Cevimeline.HCl
Cevimelinum
D00661
D07667
DB00185
Evoxac
Evoxac (TN)
FKS-508
Fks 508
HSDB 7286
LS-145782
LS-172037
NCGC00181793-01
SND 5008, AF-102B, FKS-508
SND-5008
SNI-2011
SNK-508
Saligren
Saligren (TN)
Sni 2011
UNII-K9V0CDQ56E
UNII-P81Q6V85NP
cevimeline hydrochloride hydrate
cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1)
8
Morphineapproved, investigationalPhase 496057-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
 
Infumorph
Kadian
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morfina
morphine
nchembio.317-comp1
nchembio.64-comp1
9
PetrolatumapprovedPhase 4898009-03-8
Synonyms:
Multi-hydrocarbon
Paraffinum album
Paraffinum flavum
Petrolatum base
Petrolatum, white
 
Petrolatum,amber
Petrolatum,white
Petroleum jelly
Soft paraffin
White petrolatum
White, soft paraffin
Yellow soft paraffin
10Titanium dioxideapprovedPhase 43713463-67-7
11
Docetaxelapproved, investigational, Approved May 1996Phase 4, Phase 3, Phase 2, Phase 1, Early Phase 11918114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
12Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Early Phase 117734
13Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 122776
14Dermatologic AgentsPhase 4, Phase 3, Phase 2, Phase 15674
15HematinicsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 11630
16Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 110355
17Pharmaceutical SolutionsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 17793
18Cholinergic AgentsPhase 4, Phase 33846
19Autonomic AgentsPhase 4, Phase 3, Phase 2, Phase 19774
20AnalgesicsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 111287
21Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14855
22AntibodiesPhase 4, Phase 3, Phase 2, Phase 16045
23Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 110884
24Alkylating AgentsPhase 4, Phase 3, Phase 2, Phase 14694
25VaccinesPhase 4, Phase 3, Phase 2, Phase 16428
26Epoetin alfaPhase 4, Phase 3, Phase 2645113427-24-0
27Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 16972
28AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 111774
29Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 112770
30ImmunoglobulinsPhase 4, Phase 3, Phase 2, Phase 16045
31Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 17171
32Antimitotic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 15498
33NarcoticsPhase 4, Phase 3, Phase 23486
34Protein Kinase InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 13612
35Central Nervous System DepressantsPhase 4, Phase 3, Phase 2, Early Phase 112806
36Anesthetics, GeneralPhase 4, Phase 32787
37Anesthetics, IntravenousPhase 4, Phase 32406
38Adjuvants, AnesthesiaPhase 4, Phase 31588
39MitomycinsPhase 4, Phase 3, Phase 2233
40Analgesics, OpioidPhase 4, Phase 3, Phase 23091
41AnestheticsPhase 4, Phase 3, Phase 29001
42Anti-Allergic AgentsPhase 41490
43mometasone furoatePhase 416883919-23-7
44arginineNutraceuticalPhase 4, Phase 2, Phase 1408
45Omega 3 Fatty AcidNutraceuticalPhase 4, Phase 2969
46
MethotrexateapprovedPhase 3, Phase 2, Phase 115181959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
 
Methopterin
Methotextrate
Methotrate
Methotrexat
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Rheumatrex
Trexall
47
AldesleukinapprovedPhase 3, Phase 2, Phase 139785898-30-2, 110942-02-4
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
 
Interleukin-2 aldesleukin
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
48TegafurapprovedPhase 3, Phase 29017902-23-7
49
Irinotecanapproved, investigationalPhase 3, Phase 2, Phase 1108097682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
50
Amifostineapproved, investigationalPhase 3, Phase 1, Phase 28120537-88-62141
Synonyms:
Amifostina
Amifostine
Amifostine Ethiofos
Amifostinum
Aminopropylaminoethyl Thiophosphate
 
Apaetp
Ethiofos
Ethyol
Gammaphos
SAPEP
WR-1065

Interventional clinical trials:

(show top 50)    (show all 1529)
idNameStatusNCT IDPhase
1Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE)Unknown statusNCT01553032Phase 4
2A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous CarcinomaUnknown statusNCT00642239Phase 4
3Epoetin Beta in Treating Anemia in Patients With Cervical CancerCompletedNCT00046969Phase 4
4Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced XerostomiaCompletedNCT00466388Phase 4
5Post-marketing Surveillance Study of Docetaxel-Based ChemotherapyCompletedNCT02972216Phase 4
6Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx CarcinomaCompletedNCT00772681Phase 4
7Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer PatientsCompletedNCT02622880Phase 4
8A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer PatientsCompletedNCT01283906Phase 4
9Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and NeckRecruitingNCT02015650Phase 4
10Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' PatientsRecruitingNCT02495064Phase 4
11Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional GastrostomyRecruitingNCT02869321Phase 4
12An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and NeckActive, not recruitingNCT00684385Phase 4
13Stereotactic Body Radiotherapy for Head and Neck TumorsActive, not recruitingNCT01344356Phase 4
14Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant RecipientsActive, not recruitingNCT02624349Phase 4
15Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck CancerUnknown statusNCT00002659Phase 3
16S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck CancerUnknown statusNCT00336947Phase 3
17Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer.Unknown statusNCT01124409Phase 3
18Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer TreatmentUnknown statusNCT00935675Phase 3
19Biomarkers in Patients With Metastatic or Recurrent Head and Neck Cancer Treated With Cisplatin and Cetuximab on ECOG-E5397Unknown statusNCT01466244Phase 3
20Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth CancerUnknown statusNCT00002747Phase 3
21Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving MethotrexateUnknown statusNCT00041613Phase 3
22Effectiveness and Safety of INGN 201 in Combination With Chemotherapy Versus Chemotherapy AloneUnknown statusNCT00041626Phase 3
23Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or OropharynxUnknown statusNCT00002702Phase 3
24Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Advanced Cancer of the Oropharynx or HypopharynxUnknown statusNCT00003627Phase 3
25Topical Imiquimod for Bowen's Disease of the Head and NeckUnknown statusNCT00384124Phase 2, Phase 3
26PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck CancerUnknown statusNCT00720070Phase 3
27Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the NasopharynxUnknown statusNCT00003637Phase 3
28Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced XerostomiaUnknown statusNCT00081029Phase 3
29Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea PolyphenolsUnknown statusNCT01496521Phase 3
30Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After EsophagectomyUnknown statusNCT01402180Phase 2, Phase 3
31Elective or Prophylactic Nodal Irradiation for Esophageal CancerUnknown statusNCT01551589Phase 3
32Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIALUnknown statusNCT01039298Phase 3
33Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the EsophagusUnknown statusNCT00002884Phase 3
34Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal CancerUnknown statusNCT00509561Phase 2, Phase 3
35Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical CancerCompletedNCT00003945Phase 3
36Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and NeckCompletedNCT00442455Phase 3
37Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese SubjectsCompletedNCT01012258Phase 3
38A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and NeckCompletedNCT01177956Phase 3
39Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT01086826Phase 3
40Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)CompletedNCT00206219Phase 3
41Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical CancerCompletedNCT00803062Phase 3
42Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the CervixCompletedNCT00064077Phase 3
43Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)CompletedNCT00122460Phase 3
44Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedNCT00401323Phase 2, Phase 3
45Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT00771641Phase 3
46DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCCCompletedNCT00496652Phase 3
47Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck CancersCompletedNCT01166542Phase 3
48Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck CancerCompletedNCT00460265Phase 3
49Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical CancerCompletedNCT00003209Phase 3
50Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary TumorCompletedNCT00047125Phase 3

Search NIH Clinical Center for Cervical Squamous Cell Carcinoma

Genetic Tests for Cervical Squamous Cell Carcinoma

About this section

Anatomical Context for Cervical Squamous Cell Carcinoma

About this section

MalaCards organs/tissues related to Cervical Squamous Cell Carcinoma:

36
Cervix, Uterus, Lung, Lymph node, Thyroid, Breast, Skin

Publications for Cervical Squamous Cell Carcinoma

About this section

Articles related to Cervical Squamous Cell Carcinoma:

(show top 50)    (show all 305)
idTitleAuthorsYear
1
Overexpression of the oncostatin-M receptor in cervical squamous cell carcinoma is associated with epithelial-mesenchymal transition and poor overall survival. (27351213)
2016
2
Involvement of myeloperoxidase gene polymorphism 463G>A in development of cervical squamous cell carcinoma. (27197583)
2016
3
Biventricular metastatic invasion from cervical squamous cell carcinoma. (27371746)
2016
4
ITPR3 gene haplotype is associated with cervical squamous cell carcinoma risk in Taiwanese women. (28036301)
2016
5
I9Np63I+ attenuates tumor aggressiveness by suppressing miR-205/ZEB1-mediated epithelial-mesenchymal transition in cervical squamous cell carcinoma. (26864590)
2016
6
The Value of Diffusion-Weighted Imaging in Predicting the Prognosis of Stage IB-IIA Cervical Squamous Cell Carcinoma After Radical Hysterectomy. (26807567)
2016
7
A comprehensive expression analysis of the MIA gene family in malignancies: MIA gene family members are novel, useful markers of esophageal, lung, and cervical squamous cell carcinoma. (27145272)
2016
8
Expression of E-, P- and N-Cadherin and Its Clinical Significance in Cervical Squamous Cell Carcinoma and Precancerous Lesions. (27223886)
2016
9
Prognostic Value of Neutrophil-Related Factors in Locally Advanced Cervical Squamous Cell Carcinoma Patients Treated with Cisplatin-Based Concurrent Chemoradiotherapy. (27087737)
2016
10
Role of difucosylated Lewis Y antigen in outcome of locally advanced cervical squamous cell carcinoma treated with cisplatin regimen. (27197582)
2016
11
Vasculogenic mimicry and hypoxia-inducible factor-1I+ expression in cervical squamous cell carcinoma. (26985936)
2016
12
Prognostic Significance of Cytokeratin 19 and Squamous Cell Cancer Antigen in Histologically Negative Sentinel Lymph Nodes of Cervical Squamous Cell Carcinoma. (27654256)
2016
13
Efficacy of neoadjuvant chemotherapy plus radical surgery in patients with bulky stage II cervical squamous cell carcinoma: A retrospective cohort study. (27131759)
2016
14
Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review. (27895779)
2016
15
Functional variant of the P2X7 receptor gene is associated with human papillomavirus-16 positive cervical squamous cell carcinoma. (27779103)
2016
16
Expression of HIF-2I+ and VEGF in Cervical Squamous Cell Carcinoma and Its Clinical Significance. (27413748)
2016
17
5-Hydroxymethylcytosine expression is associated with poor survival in cervical squamous cell carcinoma. (26851753)
2016
18
Integrative genomic and network analysis identified novel genes associated with the development of advanced cervical squamous cell carcinoma. (27641506)
2016
19
MRI in the synchronic chemoradiotherapy of cervical squamous cell carcinoma. (27352568)
2016
20
TRPV6 is a prognostic marker in early-stage cervical squamous cell carcinoma. (27747588)
2016
21
High Expression of KIF20A Is Associated with Poor Overall Survival and Tumor Progression in Early-Stage Cervical Squamous Cell Carcinoma. (27941992)
2016
22
A retrospective study of neoadjuvant chemotherapy plus radical hysterectomy versus radical hysterectomy alone in patients with stage II cervical squamous cell carcinoma presenting as a bulky mass. (27695343)
2016
23
Functional significance of transgelin-2 in uterine cervical squamous cell carcinoma. (26891454)
2016
24
Increased expression of long non-coding RNA XIST predicts favorable prognosis of cervical squamous cell carcinoma subsequent to definitive chemoradiation therapy. (27899965)
2016
25
DEPTOR promotes survival of cervical squamous cell carcinoma cells and its silencing induces apoptosis through downregulating PI3K/AKT and by up-regulating p38 MAP kinase. (26992219)
2016
26
Scalp Metastasis as a Presenting Symptom of Cervical Squamous Cell Carcinoma. (27105328)
2016
27
UHRF1 gene silencing inhibits cell proliferation and promotes cell apoptosis in human cervical squamous cell carcinoma CaSki cells. (27431502)
2016
28
The Prognosis and Risk Stratification Based on Pelvic Lymph Node Characteristics in Patients With Locally Advanced Cervical Squamous Cell Carcinoma Treated With Concurrent Chemoradiotherapy. (27400321)
2016
29
ZEB1 promotes the progression and metastasis of cervical squamous cell carcinoma via the promotion of epithelial-mesenchymal transition. (26617850)
2015
30
Immunohistochemical Expression and Prognostic Significance of CD97 and its Ligand DAF in Human Cervical Squamous Cell Carcinoma. (26107567)
2015
31
Putative stem cell markers in cervical squamous cell carcinoma are correlated with poor clinical outcome. (26499463)
2015
32
The Number of Positive Pelvic Lymph Nodes and Multiple Groups of Pelvic Lymph Node Metastasis Influence Prognosis in Stage IA-IIB Cervical Squamous Cell Carcinoma. (26228223)
2015
33
Combination of external beam radiotherapy and Californium (Cf)-252 neutron intracavity brachytherapy is more effective in control of cervical squamous cell carcinoma than that of cervical adenocarcinoma. (26271794)
2015
34
Expressions and clinical significance of autophagy-related markers Beclin1, LC3, and EGFR in human cervical squamous cell carcinoma. (26346666)
2015
35
Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by inhibiting Wnt/I^-catenin signaling. (26427870)
2015
36
Matrix metalloproteinases 2 and 9, their endogenous regulators, and angiotensin-converting enzyme in cervical squamous cell carcinoma]. (26978018)
2015
37
Genetic susceptibility to cervical squamous cell carcinoma is associated with HLA-DPB1 polymorphisms in Taiwanese women. (26031576)
2015
38
The landscape of alternative splicing in cervical squamous cell carcinoma. (25565867)
2015
39
Invasion of uterine cervical squamous cell carcinoma cells is facilitated by locoregional interaction with cancer-associated fibroblasts via activating transforming growth factor-beta. (25434636)
2015
40
ALEX1 may be a novel biomarker for human cervical squamous cell carcinoma. (26464700)
2015
41
Expression and significance of LRIG3 in human cervical squamous cell carcinoma. (26390694)
2015
42
Transcriptome profiling of the cancer and adjacent nontumor tissues from cervical squamous cell carcinoma patients by RNA sequencing. (25586346)
2015
43
A rare case of HPV-negative cervical squamous cell carcinoma. (25675193)
2015
44
Tumor invasion depth is a useful pathologic assessment for predicting outcomes in cervical squamous cell carcinoma after neoadjuvant radiotherapy. (26537362)
2015
45
Astrocyte elevated gene-1 promotes progression of cervical squamous cell carcinoma by inducing epithelial-mesenchymal transition via Wnt signaling. (25695541)
2015
46
A Functional Polymorphism in the Promoter of MiR-143/145 Is Associated With the Risk of Cervical Squamous Cell Carcinoma in Chinese Women: A Case-Control Study. (26252302)
2015
47
P16INK4A and survivin: Diagnostic and prognostic markers in cervical intraepithelial neoplasia and cervical squamous cell carcinoma. (25910412)
2015
48
Expression of Vimentin and Ki-67 Proteins in Cervical Squamous Cell Carcinoma and their Relationships with Clinicopathological Features. (26028085)
2015
49
EGFR Promoter Methylation, EGFR Mutation, and HPV Infection in Chinese Cervical Squamous Cell Carcinoma. (25789535)
2015
50
HK2 is a radiation resistant and independent negative prognostic factor for patients with locally advanced cervical squamous cell carcinoma. (26097593)
2015

Variations for Cervical Squamous Cell Carcinoma

About this section

Cosmic variations for Cervical Squamous Cell Carcinoma:

8 (show top 50)    (show all 53)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM715FGFR3cervix,NS,carcinoma,squamous cell carcinomac.746C>Gp.S249C12
2COSM518KRAScervix,NS,carcinoma,squamous cell carcinomac.34G>Cp.G12R12
3COSM43896TP53cervix,NS,carcinoma,squamous cell carcinomac.818G>Cp.R273P12
4COSM580NRAScervix,NS,carcinoma,squamous cell carcinomac.181C>Ap.Q61K12
5COSM49175FGFR2cervix,NS,carcinoma,squamous cell carcinomac.1976A>Tp.K659M12
6COSM499HRAScervix,NS,carcinoma,squamous cell carcinomac.182A>Gp.Q61R12
7COSM763PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.1633G>Ap.E545K12
8COSM12459PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.1637A>Gp.Q546R12
9COSM483HRAScervix,NS,carcinoma,squamous cell carcinomac.35G>Tp.G12V12
10COSM10725TP53cervix,NS,carcinoma,squamous cell carcinomac.701A>Gp.Y234C12
11COSM13646CDKN2Acervix,NS,carcinoma,squamous cell carcinomac.392G>Tp.R131L12
12COSM773PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.3129G>Tp.M1043I12
13COSM10648TP53cervix,NS,carcinoma,squamous cell carcinomac.524G>Ap.R175H12
14COSM44029TP53cervix,NS,carcinoma,squamous cell carcinomac.550G>Ap.D184N12
15COSM480HRAScervix,NS,carcinoma,squamous cell carcinomac.34G>Ap.G12S12
16COSM45507TP53cervix,NS,carcinoma,squamous cell carcinomac.806G>Cp.S269T12
17COSM760PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.1624G>Ap.E542K12
18COSM10889TP53cervix,NS,carcinoma,squamous cell carcinomac.536A>Gp.H179R12
19COSM29464STK11cervix,NS,carcinoma,squamous cell carcinomac.169G>Tp.E57*12
20COSM497HRAScervix,NS,carcinoma,squamous cell carcinomac.181C>Gp.Q61E12
21COSM775PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.3140A>Gp.H1047R12
22COSM10705TP53cervix,NS,carcinoma,squamous cell carcinomac.586C>Tp.R196*12
23COSM10659TP53cervix,NS,carcinoma,squamous cell carcinomac.817C>Tp.R273C12
24COSM11356TP53cervix,NS,carcinoma,squamous cell carcinomac.726C>Gp.C242W12
25COSM12458PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.1634A>Cp.E545A12
26COSM46185TP53cervix,NS,carcinoma,squamous cell carcinomac.775G>Cp.D259H12
27COSM17442PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.1624G>Cp.E542Q12
28COSM5731CTNNB1cervix,NS,carcinoma,squamous cell carcinomac.113G>Cp.G38A12
29COSM29465STK11cervix,NS,carcinoma,squamous cell carcinomac.320A>Gp.H107R12
30COSM45259TP53cervix,NS,carcinoma,squamous cell carcinomac.301A>Tp.K101*12
31COSM5662CTNNB1cervix,NS,carcinoma,squamous cell carcinomac.110C>Tp.S37F12
32COSM43662TP53cervix,NS,carcinoma,squamous cell carcinomac.868C>Ap.R290S12
33COSM766PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.1636C>Ap.Q546K12
34COSM10749TP53cervix,NS,carcinoma,squamous cell carcinomac.830G>Tp.C277F12
35COSM1168056PIK3CAcervix,NS,carcinoma,squamous cell carcinomac.3145G>Tp.G1049C12
36COSM552KRAScervix,NS,carcinoma,squamous cell carcinomac.182A>Gp.Q61R12
37COSM3734673STK11cervix,NS,carcinoma,squamous cell carcinomac.597G>Cp.E199D12
38COSM12469CDKN2Acervix,NS,carcinoma,squamous cell carcinomac.244G>Ap.V82M12
39COSM5730CTNNB1cervix,NS,carcinoma,squamous cell carcinomac.122C>Ap.T41N12
40COSM11483TP53cervix,NS,carcinoma,squamous cell carcinomac.848G>Ap.R283H12
41COSM551KRAScervix,NS,carcinoma,squamous cell carcinomac.182A>Cp.Q61P12
42COSM555KRAScervix,NS,carcinoma,squamous cell carcinomac.183A>Tp.Q61H12
43COSM10662TP53cervix,NS,carcinoma,squamous cell carcinomac.743G>Ap.R248Q12
44COSM43624TP53cervix,NS,carcinoma,squamous cell carcinomac.875A>Gp.K292R12
45COSM43660TP53cervix,NS,carcinoma,squamous cell carcinomac.719G>Tp.S240I12
46COSM517KRAScervix,NS,carcinoma,squamous cell carcinomac.34G>Ap.G12S12
47COSM13778CDKN2Acervix,NS,carcinoma,squamous cell carcinomac.376G>Ap.V126I12
48COSM120958NFE2L2cervix,NS,carcinoma,squamous cell carcinomac.235G>Cp.E79Q12
49COSM521KRAScervix,NS,carcinoma,squamous cell carcinomac.35G>Ap.G12D12
50COSM5089PTENcervix,NS,carcinoma,squamous cell carcinomac.517C>Tp.R173C12

Copy number variations for Cervical Squamous Cell Carcinoma from CNVD:

6 (show all 38)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
11914445115100000GainPDCD6Cervical squamous cell carcinoma
21914665118500000GainPOLSCervical squamous cell carcinoma
31914675118500000GainSDHACervical squamous cell carcinoma
41914685118500000GainSRD5A1Cervical squamous cell carcinoma
51916245142400000GainRPL37Cervical squamous cell carcinoma
61916255142400000GainSKP2Cervical squamous cell carcinoma
71916275142400000GainSLC1A3Cervical squamous cell carcinoma
8191642514400000GainIRX2Cervical squamous cell carcinoma
9191643514400000GainNDUFS6Cervical squamous cell carcinoma
10191644514400000GainTERTCervical squamous cell carcinoma
11191646514400000GainTRIP13Cervical squamous cell carcinoma
12191726518200000GainIRX4Cervical squamous cell carcinoma
1319545151510000018500000GainANKHCervical squamous cell carcinoma
1419545251510000018500000GainZNF622Cervical squamous cell carcinoma
1519545351510000023300000GainMYO10Cervical squamous cell carcinoma
1619545451510000029300000GainBASP1Cervical squamous cell carcinoma
1719872552930000034400000GainDROSHACervical squamous cell carcinoma
1819872652930000034400000GainGOLPH3Cervical squamous cell carcinoma
1919872752930000034400000GainMTMR12Cervical squamous cell carcinoma
2019872852930000034400000GainSUB1Cervical squamous cell carcinoma
2119907653440000038500000GainDNAJA5Cervical squamous cell carcinoma
2219907853440000038500000GainLMBRD2Cervical squamous cell carcinoma
2319907953440000038500000GainNIPBLCervical squamous cell carcinoma
2419908053440000038500000GainRAD1Cervical squamous cell carcinoma
2519908253440000038500000GainTARSCervical squamous cell carcinoma
2619908353440000038500000GainWDR70Cervical squamous cell carcinoma
2719938453850000042400000GainNUP155Cervical squamous cell carcinoma
2819938553850000042400000GainOXCT1Cervical squamous cell carcinoma
2919968454240000045800000GainCCL28Cervical squamous cell carcinoma
3019968554240000045800000GainFBXO4Cervical squamous cell carcinoma
3119968654240000045800000GainPAIP1Cervical squamous cell carcinoma
3219968954240000047700000GainZNF131Cervical squamous cell carcinoma
33199835544000006000000GainKIAA0947Cervical squamous cell carcinoma
342024515820000015100000GainCCT5Cervical squamous cell carcinoma
352024525820000015100000GainDAPCervical squamous cell carcinoma
362024545820000015100000GainMARCH-VICervical squamous cell carcinoma
372024625820000023300000GainZFYVE16Cervical squamous cell carcinoma
382024645820000045800000GainOSRFCervical squamous cell carcinoma

Expression for genes affiliated with Cervical Squamous Cell Carcinoma

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Cervical Squamous Cell Carcinoma patients vs. healthy controls: 35 (show all 33)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1CRNNcornulinUterus-5.620.000
2KRT1keratin 1, type IIUterus-5.320.000
3UPK1Auroplakin 1AUterus-4.790.000
4MALmal, T-cell differentiation proteinUterus-4.730.000
5KRT4keratin 4, type IIUterus-4.450.000
6SPRR3small proline-rich protein 3Uterus-4.430.000
7DSG1desmoglein 1Uterus-4.270.000
8CDKN2Acyclin-dependent kinase inhibitor 2AUterus+4.210.000
9CRISP3cysteine-rich secretory protein 3Uterus-4.130.000
10CRCT1cysteine-rich C-terminal 1Uterus-3.920.000
11SPINK5serine peptidase inhibitor, Kazal type 5Uterus-3.670.000
12SLURP1secreted LY6/PLAUR domain containing 1Uterus-3.540.000
13APOC1apolipoprotein C-IUterus+3.530.000
14HOPXHOP homeoboxUterus-3.510.000
15EDN3endothelin 3Uterus-3.480.000
16FANCIFanconi anemia, complementation group IUterus+3.420.000
17SYNGR3synaptogyrin 3Uterus+3.410.000
18CRYABcrystallin, alpha BUterus-3.390.000
19KRT13keratin 13, type IUterus-3.350.004
20MCM5minichromosome maintenance complex component 5Uterus+3.310.000
21ALOX12arachidonate 12-lipoxygenaseUterus-3.260.000
22PPP1R3Cprotein phosphatase 1, regulatory subunit 3CUterus-3.230.000
23SCELsciellinUterus-3.190.000
24NTSneurotensinUterus+3.190.006
25NUSAP1nucleolar and spindle associated protein 1Uterus+3.170.000
26IVLinvolucrinUterus-3.140.000
27IL1R2interleukin 1 receptor, type IIUterus-3.140.000
28CFDcomplement factor D (adipsin)Uterus-3.130.000
29SOSTDC1sclerostin domain containing 1Uterus-3.080.000
30ESR1estrogen receptor 1Uterus-3.060.000
31PAMR1peptidase domain containing associated with muscle regeneration 1Uterus-3.060.000
32ENDOUendonuclease, polyU-specificUterus-3.040.000
33HOXC6homeobox C6Uterus+3.010.000

Search GEO for disease gene expression data for Cervical Squamous Cell Carcinoma.

Pathways for genes affiliated with Cervical Squamous Cell Carcinoma

About this section

Pathways related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.6CDKN2A, TP53, TP63
29.5CDH1, CTNNB1
3
Show member pathways
9.4RASSF1, SKP2, TP53
49.1CDH1, CTNNB1, TP53
59.1CTNNB1, EGFR, TP53
69.1CDH1, CTNNB1, EGFR
79.1CDH1, CTNNB1, EGFR
8
Show member pathways
9.0CDH1, CDKN2A, SKP2, TP53
99.0CDKN2A, EGFR, RASSF1, TP53, TP63
108.9CDKN2A, CTNNB1, EGFR, TP53
118.9CDKN2A, MKI67, SKP2, TP53, TP63
128.8CDH1, CTNNB1, RASSF1, SOX2
138.8CDKN2A, CTNNB1, HLA-DRB1, TP53
148.7CDH1, CTNNB1, EGFR, TP53
158.7CDH1, CTNNB1, EGFR, TP53
16
Show member pathways
8.7CDH1, CTNNB1, EGFR, TP53
17
Show member pathways
8.6CDH1, CTNNB1, DAPK1, TP53, TP63
188.4CDH1, CDKN2A, DAPK1, EGFR, RASSF1, TP53
19
Show member pathways
8.3CDH1, CDKN2A, CTNNB1, EGFR, RASSF1, TP53
207.5CDH1, CDKN2A, CTNNB1, DAPK1, EGFR, RASSF1

GO Terms for genes affiliated with Cervical Squamous Cell Carcinoma

About this section

Cellular components related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1apical junction complexGO:004329610.3CDH1, CTNNB1
2catenin complexGO:001634210.3CDH1, CTNNB1
3flotillin complexGO:00166009.5CDH1, CTNNB1
4cytoplasmGO:00057375.1CDH1, CDKN2A, CTNNB1, DAPK1, DNAJC9, EGFR

Biological processes related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
idNameGO IDScoreTop Affiliating Genes
1DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:000697810.5TP53, TP63
2mitotic G1 DNA damage checkpointGO:003157110.5TP53, TP63
3Ras protein signal transductionGO:000726510.3CDKN2A, RASSF1, TP53
4cellular response to indole-3-methanolGO:007168110.2CDH1, CTNNB1
5cellular response to lithium ionGO:007128510.2CDH1, CTNNB1
6midgut developmentGO:000749410.1CTNNB1, EGFR
7regulation of cysteine-type endopeptidase activity involved in apoptotic processGO:004328110.0SOX2, TP63
8cell cycle arrestGO:000705010.0CDKN2A, RASSF1, SOX2, TP53
9replicative senescenceGO:00903999.9CDKN2A, TP53
10positive regulation of transcription, DNA-templatedGO:00458939.0CDH1, CTNNB1, SOX2, TP53, TP63
11cell proliferationGO:00082839.0CTNNB1, EGFR, MKI67, SKP2, TP53
12regulation of apoptotic processGO:00429818.8CTNNB1, DAPK1, SKP2, TP53, TP63

Molecular functions related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protease bindingGO:00020209.7SERPINB3, SERPINB4, TP53
2protein phosphatase bindingGO:00199039.7CTNNB1, EGFR, TP53
3double-stranded DNA bindingGO:00036909.5CTNNB1, EGFR, TP53, TP63
4transcription regulatory region DNA bindingGO:00442128.8CTNNB1, SOX2, TP53, TP63

Sources for Cervical Squamous Cell Carcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet